Early evidence that docetaxel may continue to be relevant in CRPC in the near future. This is very important for OGXI.
[quote]In contrast, for pts treated with D, 10 (71%) had a decline in PSA; 6 (43%) with a > 50% maximum PSA decline. Of 6 pts with measurable disease, 2 (33%) had an objective response. The median time to progression for the D cohort was 129 days (range 60 – 294). Conclusions: Although the cohort size is small, and post-AA therapy was not randomized, these data provide preliminary support for the hypothesis that CRPC progressing on AA is cross-resistant to further androgen synthesis inhibition with keto. Contrary to other reports, [b]prior treatment with AA does not appear to decrease the likelihood of subsequent response to D[/b], but this observation requires prospective validation.[/quote]